19 February 2018
This month on Synapse
Robert Vidal and Belinda Lavin discuss the CJEU’s ruling on the relation between pharmaceutical regulatory law and EU competition law.
Belinda Lavin examines the opinion of Advocate General Tanchev on the interplay between the Specific Mechanism and SPC protection.
Paul England rounds-up the issues being referred to the CJEU on the subject of exactly what products can be protected by an SPC.
Supplementary protection certificates 2: how must a product be identified in a patent for the purpose of SPC protection?
Paul England rounds-up the issues being referred to the CJEU on the subject of how exactly products protected by an SPC must be specified in the underlying ‘basic patent in force’.